The FDA expanded the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) Friday to include treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

Shares of argenx (ARGX) rose after the company announced the FDA approval of Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (‘CIDP’). The product label is broad ...

Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune disease that can cause severe numbness, weakness and disability. In a recent interview hosted by Sanofi, Dr. Jeffrey ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients were ...

Guillain-Barr syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are rare autoimmune conditions in which your immune system mistakenly ...

Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis (MG) and initial results from Period 1 of a mid-stage study of the ...